1. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
- Author
-
Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, and Bokemeyer C
- Subjects
- Acetylglucosaminidase urine, Adult, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Breast Neoplasms drug therapy, Cisplatin administration & dosage, Creatinine blood, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate drug effects, Humans, Ifosfamide administration & dosage, Kidney pathology, Kidney Function Tests, Lymphoma, Non-Hodgkin drug therapy, Magnesium blood, Male, Middle Aged, Proteinuria, Testicular Neoplasms drug therapy, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin adverse effects, Ifosfamide adverse effects, Kidney drug effects, Neoplasms drug therapy
- Abstract
The nephrotoxic effects of different platinum compounds based combination chemotherapies were compared. Chemotherapy consisted of either cisplatin fractionated over 5 days (5 x 20 mg/m2) or given as a single-day infusion (1 x 50 mg/m2) plus ifosfamide (4 g/m2) or high-dose chemotherapy was applied including carboplatin (3 x 500 mg/m2) and ifosfamide (3 x 4 g/m2) fractionated over three consecutive days. Conventional parameters such as serum creatinine and glomerular filtration rate (GFR), as well as urinary protein excretion of N-acetyl-beta-D-glucosaminidase (NAG)) and alpha 1-micro-globulin were assessed in 52 patients. Fractionation over 5 days without adding other nephrotoxic agents, i.e. ifosfamide, prevented decreases in GFR following cisplatin, whereas the combination of conventional dose cisplatin and ifosfamide, given as a single-day infusion, and high-dose carboplatin/ifosfamide yielded a pronounced fall of GFR. All groups showed increases in the urinary excretion levels of serum derived proteins and NAG, but with significant differences; about 2 to 3-fold for 5-days cisplatin, 3 to 5-fold for single-day cisplatin/ifosfamide, and 20 to 35-fold for high-dose chemotherapy. Thus, conventional approaches can reduce but not prevent the nephrotoxicity of cisplatin-based chemotherapy. In particular, high-dose chemotherapy regimens including carboplatin and ifosfamide are associated with comparable or even higher nephrotoxicity to single-day cisplatin/ifosfamide. In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved.
- Published
- 2000